Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology

The U.S. specialty pharma continues its multi-year effort to expand into biologics by licensing in the Australian biotech's adult stem cell technology for cardiovascular, oncology, and neurodegenerative indications.